#151311

Anti-E2F6 [TFE61]

Cat. #151311

Anti-E2F6 [TFE61]

Cat. #: 151311

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-5 days

Target: E2F-6

Class: Monoclonal

Application: IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: European Institute of Oncology

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-E2F6 [TFE61]
  • Clone: TFE61
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 38 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IF ; IP ; WB
  • Description: E2F-6 is a member of the E2F transcription factor protein family. E2F family members play a crucial role in control of the cell cycle and of the action of tumour suppressor proteins.
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: Hela cells or K-562 nuclear extract

Target Details

  • Target: E2F-6
  • Molecular weight: 38 kDa
  • Tissue cell line specificity: Hela cells or K-562 nuclear extract
  • Target background: E2F-6 is a member of the E2F transcription factor protein family. E2F family members play a crucial role in control of the cell cycle and of the action of tumour suppressor proteins.

Applications

  • Application: IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Furuta et al. 2010. Carcinogenesis. 31(5):766-76. PMID: 19843643.
  • miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
  • Kozaki et al. 2008. Cancer Res. 68(7):2094-105. PMID: 18381414.
  • Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer.